跳至主要内容
临床试验/NCT00004428
NCT00004428已完成1 期

Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis

FDA Office of Orphan Products Development0 个研究点目标入组 35 人开始时间: 1997年9月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
35

研究概览

简要总结

OBJECTIVES: I. Evaluate the safety of ascending doses of CPX administered to adult patients with mild cystic fibrosis.

II. Evaluate the pharmacokinetics of ascending doses of CPX in this patient population.

详细描述

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, dose escalation study.

There are 7 experimental cohorts, each treated with a different oral dose of CPX or placebo. Within each cohort, 4 patients receive a single dose of CPX and 1 patient receives placebo. Each patient is monitored 24 hours postdose. Escalation to the next dose level for each subsequent cohort begins only after the safety data obtained from the previous cohort is reviewed and found not to limit dose escalation.

All patients return for a follow up evaluation 1 week after dosing.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •PROTOCOL ENTRY CRITERIA:
  • •Mild cystic fibrosis
  • •Not pregnant or nursing Negative pregnancy test

排除标准

  • 未提供

研究者

发起方
FDA Office of Orphan Products Development
申办方类型
Fed

相似试验